AbbVie Inc. Intangible Assets, Gross (Excluding Goodwill)
AbbVie Inc. (ABBV) had Intangible Assets, Gross (Excluding Goodwill) of $94.73 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Goodwill and Other
us-gaap:IntangibleAssetsGrossExcludingGoodwill · last filed 2026-08-03
- 2026-06-30: Intangible Assets, Gross (Excluding Goodwill) $94.73B.
- 2026-03-31: Intangible Assets, Gross (Excluding Goodwill) $94.80B.
- 2025-12-31: Intangible Assets, Gross (Excluding Goodwill) $94.87B.
- 2025-09-30: Intangible Assets, Gross (Excluding Goodwill) $94.76B.
| Period end | Intangible Assets, Gross (Excluding Goodwill) |
|---|---|
| 2026-06-30 | $94.73B 10-Q · filed 2026-08-03 |
| 2026-03-31 | $94.80B 10-Q · filed 2026-05-08 |
| 2025-12-31 | $94.87B 10-Q · filed 2026-08-03 |
| 2025-09-30 | $94.76B 10-Q · filed 2025-11-04 |
| 2025-06-30 | $95.79B 10-Q · filed 2025-08-04 |
| 2025-03-31 | $95.28B 10-Q · filed 2025-05-09 |
| 2024-12-31 | $94.94B 10-K · filed 2026-02-20 |
| 2024-09-30 | $99.73B 10-Q · filed 2024-11-04 |
| 2024-06-30 | $91.39B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $92.11B 10-Q · filed 2024-05-03 |
| 2023-12-31 | $83.64B 10-K · filed 2025-02-14 |
| 2023-09-30 | $85.07B 10-Q · filed 2023-11-06 |
| 2023-06-30 | $96.47B 10-Q · filed 2023-08-07 |
| 2023-03-31 | $96.39B 10-Q · filed 2023-05-05 |
| 2022-12-31 | $97.08B 10-K · filed 2024-02-20 |
| 2022-09-30 | $96.47B 10-Q · filed 2022-11-04 |
| 2022-06-30 | $97.60B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $97.97B 10-Q · filed 2022-05-06 |
| 2021-12-31 | $98.10B 10-K · filed 2023-02-17 |
| 2021-09-30 | $97.82B 10-Q · filed 2021-11-02 |
| 2021-06-30 | $97.81B 10-Q · filed 2021-08-02 |
| 2021-03-31 | $97.82B 10-Q · filed 2021-05-07 |
| 2020-12-31 | $97.41B 10-K · filed 2022-02-18 |
| 2020-09-30 | $87.32B 10-Q · filed 2020-11-04 |
| 2020-06-30 | $87.01B 10-Q · filed 2020-08-04 |
| 2019-12-31 | $27.34B 10-K · filed 2021-02-19 |
| 2019-09-30 | $27.40B 10-Q · filed 2019-11-06 |
| 2019-06-30 | $28.44B 10-Q · filed 2019-08-05 |
| 2019-03-31 | $28.65B 10-Q · filed 2019-05-03 |
| 2018-12-31 | $28.66B 10-K · filed 2020-02-21 |
| 2018-09-30 | $33.73B 10-Q · filed 2018-11-07 |
| 2018-06-30 | $33.69B 10-Q · filed 2018-08-07 |
| 2018-03-31 | $33.95B 10-Q · filed 2018-05-04 |
| 2017-12-31 | $33.95B 10-K · filed 2019-02-27 |
| 2017-09-30 | $34.31B 10-Q · filed 2017-11-07 |
| 2017-06-30 | $34.24B 10-Q · filed 2017-08-07 |
| 2017-03-31 | $34.27B 10-Q · filed 2017-05-05 |
| 2016-12-31 | $34.26B 10-K · filed 2018-02-16 |
| 2016-09-30 | $34.28B 10-Q · filed 2016-11-07 |
| 2016-06-30 | $34.41B 10-Q · filed 2016-08-05 |
| 2016-03-31 | $24.65B 10-Q · filed 2016-05-06 |
| 2015-12-31 | $24.68B 10-K · filed 2017-02-17 |
| 2015-09-30 | $24.65B 10-Q · filed 2015-11-06 |
| 2015-06-30 | $24.64B 10-Q · filed 2015-08-07 |
| 2015-03-31 | $6.11B 10-Q · filed 2015-05-08 |
| 2014-12-31 | $6.09B 10-K · filed 2016-02-19 |
| 2014-09-30 | $6.13B 10-Q · filed 2014-11-07 |
| 2014-06-30 | $6.20B 10-Q · filed 2014-08-07 |
| 2014-03-31 | $6.21B 10-Q · filed 2014-05-09 |
| 2013-12-31 | $6.18B 10-K · filed 2015-02-20 |
| 2013-09-30 | $6.18B 10-Q · filed 2013-11-12 |
| 2012-12-31 | $6.09B 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |